BERWYN, PA — AscellaHealth has unveiled its latest Specialty & Rare Pipeline Digest™ for the second quarter of 2024. This quarterly publication is known for its extensive coverage of new, pending, and upcoming launches in specialty and rare disease drugs, cell and gene therapies (CGT), biosimilars, and generics.
“The Q2 2024 Digest indicates a notable increase in specialty drug approvals and the introduction of additional cell and gene therapies compared to the previous quarter,” said Andy Szczotka, PharmD, Chief Pharmacy Officer at AscellaHealth. “This upward trend highlights the essential role of AscellaHealth in addressing the needs of millions worldwide affected by complex, chronic conditions or rare diseases.”
This digital publication serves as a critical resource for stakeholders and decision-makers in the specialty drug market. AscellaHealth’s commitment to providing timely product updates and insights helps partners, clients, and the entire specialty pharmaceutical ecosystem stay informed and prepared.
“Recognized as an important resource for the industry, The Specialty & Rare Pipeline Digest™ captures key data demonstrating the rapid growth of the specialty pharmaceutical market,” said Dea Belazi, CEO of AscellaHealth. “As the number of approved drugs rises, so does the need for specialized care and innovative solutions to ensure patient access and adherence to treatment. These trends largely account for the growth of AscellaHealth as a single-source industry partner, providing end-to-end, global solutions that result in streamlined commercialization of specialty drugs, cost savings for clients, and an optimal treatment journey for patients and caregivers.”
The latest Digest marks a significant milestone in AscellaHealth’s mission to support the specialty drug market and improve patient outcomes through comprehensive and accessible information.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.